Onco Therapies Limited, a wholly owned subsidiary of Strides Arcolab Limited (Strides) has received US FDA approvals for Cisplatin injection, 1 mg/mL packages in 50 mL and 100 mL multiple dose vials.

Cisplatin is a chemotherapy drug. It is used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas, and germ cell tumours.

Cisplatin is amongst the products in the drug shortage list of US FDA.  According to IMS data, the US market for generic Cisplatin is approximately USD 10 million.

Cisplatin is part of the oncology portfolio licensed to Pfizer in January 2010 for the US market and expected to be launched shortly.